Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Acquisitions & Divestments: 2013-2022

Historic Change in Acquisitions & Divestments for Catalyst Pharmaceuticals (CPRX) over the last 5 years, with Sep 2022 value amounting to $9.9 million.

  • Catalyst Pharmaceuticals' Change in Acquisitions & Divestments was N/A to $9.9 million in Q3 2022 from the same period last year, while for Sep 2022 it was $56.5 million, marking a year-over-year change of. This contributed to the annual value of $19.2 million for FY2022, which is N/A change from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Change in Acquisitions & Divestments of $9.9 million as of Q3 2022, which was up 97.36% from $5.0 million recorded in Q1 2020.
  • Over the past 5 years, Catalyst Pharmaceuticals' Change in Acquisitions & Divestments peaked at $31.7 million during Q4 2019, and registered a low of $5.0 million during Q1 2020.
  • In the last 2 years, Catalyst Pharmaceuticals' Change in Acquisitions & Divestments had a median value of $7.4 million in 2020 and averaged $7.4 million.
  • In the last 5 years, Catalyst Pharmaceuticals' Change in Acquisitions & Divestments spiked by 122.95% in 2019 and then crashed by 75.49% in 2020.
  • Over the past 4 years, Catalyst Pharmaceuticals' Change in Acquisitions & Divestments (Quarterly) stood at $14.2 million in 2018, then surged by 122.95% to $31.7 million in 2019, then plummeted by 75.49% to $5.0 million in 2020, then reached $9.9 million in 2022.
  • Its last three reported values are $9.9 million in Q3 2022, $5.0 million for Q1 2020, and $31.7 million during Q4 2019.